<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01677026</url>
  </required_header>
  <id_info>
    <org_study_id>CP-004</org_study_id>
    <nct_id>NCT01677026</nct_id>
  </id_info>
  <brief_title>Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache</brief_title>
  <official_title>Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autonomic Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Autonomic Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the Registry are to:

        1. Monitor the transfer of the ATI Neurostimulation System and its safety/clinical
           performance to a larger number of centers in the post market phase and

        2. Collect additional evidence to support reimbursement and clinical acceptance and long
           term follow up
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Character of usability and acceptance of the ATI Neurostimulation System, as evaluated by the following:</measure>
    <time_frame>Through study completion</time_frame>
    <description>Implantation of ATI Neurostimulator within the pterygopalatine fossa
Explant and lead-revision rates and reasons</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of patient response to therapy, as evaluated by the following:</measure>
    <time_frame>Through study completion</time_frame>
    <description>Patient acceptance of the therapy
Responder Analysis, where a responder is any patient who achieves Effective Therapy in at least 50% of evaluable attacks, a 50% attack frequency attack decrease relative to Baseline, or both
Disability and Quality of Life as characterized by the HIT-6 and SF-36v2 compared to Baseline
Subject Overall Evaluation of Therapy
Change in use of acute medications compared to Baseline
Change in preventive medication use and work status compared to Baseline</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cluster Headache</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who meet the CE marked labeling for cluster headache for the ATI Neurostimulation
        System.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject meets CE marked labeling for cluster headache.

          -  Subject's typical cluster headache bouts last a minimum of 16 weeks, in the opinion of
             the Investigator.

          -  Subject agrees to maintain current preventive headache medication regimens (no change
             in type, frequency or dose except to manage tolerability) from Study Enrollment
             through the completion of the Therapy Evaluation Period.

          -  Subject has the ability to read, comprehend and to reliably record information as
             required by the Protocol.

          -  Subject is able to provide written informed consent prior to participation in the
             study.

        Exclusion Criteria:

          -  Subject has had a change in type, dosage or frequency of taking preventive headache
             medications &lt; one (1) month prior to Study Enrollment.

          -  Per the CE marked labeling: In the opinion of the Investigator, subject has bony
             facial deformities, inappropriate surgical anatomy or has had facial surgery in the
             surgical area on the same side as the planned surgery that would prevent the proper
             placement of the ATI Neurostimulator.

          -  Subject has other significant pain problem that might confound the study assessments
             in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arne May, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berlin Charite Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik und Poliklinik</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Center, Dept. Of Neurology, Univ. Duisburg-Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Jena Klinik f. Neurologie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fur Mund-, Kiefer-und Gesichtschirurgie, Rotes</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Migraine- und Kopfschmerzklinik Konigstein</name>
      <address>
        <city>Konigstein</city>
        <zip>D-61462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie &amp; Kopfschmerzzentrum Munchner Freiheit</name>
      <address>
        <city>Munich</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Munich-Klinikum der Universitat Munchen Neurologische Klinik und Poliklinik</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Munster, Klinik und Poliklinik fur Neurologie</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2012</study_first_submitted>
  <study_first_submitted_qc>August 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2012</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Cluster Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

